• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HP To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

    11/13/23 8:32:28 AM ET
    $AXS
    $BBDC
    $CCAP
    $GDRX
    Property-Casualty Insurers
    Finance
    Diversified Financial Services
    Finance
    Get the next $AXS alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

    • Citigroup raised HP Inc. (NYSE:HPQ) price target from $31 to $33. Citigroup analyst Asiya Merchant upgraded the stock from Neutral to Buy. HP shares rose 2.2% to close at $27.62 on Friday. See how other analysts view this stock.
    • UBS increased the price target for Noah Holdings Limited (NYSE:NOAH) from $16.3 to $18. UBS analyst Helen Li upgraded the stock from Neutral to Buy. Noah Holdings shares gained 1.6% to $11.57 in pre-market trading. See how other analysts view this stock.
    • Piper Sandler slashed Health Catalyst, Inc. (NASDAQ:HCAT) price target from $12 to $11. Piper Sandler analyst Jessica Tassan upgraded Health Catalyst from Neutral to Overweight. Health Catalyst shares gained 3.1% to $6.92 in pre-market trading. See how other analysts view this stock.
    • Keefe, Bruyette & Woods increased the price target for AXIS Capital Holdings Limited (NYSE:AXS) from $59 to $66. Keefe, Bruyette & Woods analyst Meyer Shields upgraded the stock from Market Perform to Outperform. AXIS Capital shares gained 0.9% to close at $53.82 on Friday. See how other analysts view this stock.
    • HC Wainwright & Co. cut the price target for Nouveau Monde Graphite Inc. (NYSE:NMG) from $9 to $8. HC Wainwright & Co. analyst Heiko Ihle maintained a Buy rating. Nouveau Monde Graphite shares gained 2.6% to $2.79 in pre-market trading. See how other analysts view this stock.
    • Wells Fargo cut Barings BDC, Inc. (NYSE:BBDC) price target from $9 to $8.5. Wells Fargo analyst Finian O'Shea downgraded the stock from Overweight to Equal-Weight. Barings BDC shares fell 1.6% to $8.80 in pre-market trading. See how other analysts view this stock.
    • B of A Securities cut Paramount Group, Inc. (NYSE:PGRE) price target from $5 to $4. B of A Securities analyst Camille Bonnel downgraded the stock from Neutral to Underperform. Paramount Group shares fell 3% to $4.27 in pre-market trading. See how other analysts view this stock.
    • Wells Fargo slashed the price target for Crescent Capital BDC, Inc. (NASDAQ:CCAP) from $16.5 to $16. Wells Fargo analyst Finian O'Shea downgraded the stock from Overweight to Equal-Weight. Crescent Capital BDC shares fell 1.4% to $16.78 in pre-market trading. See how other analysts view this stock.
    • Barclays cut Waters Corporation (NYSE:WAT) price target from $270 to $230. Barclays analyst Luke Sergott downgraded the stock from Equal-Weight to Underweight. Waters shares gained 1.1% to close at $255.92 on Friday. See how other analysts view this stock.
    • Goldman Sachs cut GoodRx Holdings, Inc. (NASDAQ:GDRX) price target from $7 to $6. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. GoodRx shares fell 1.7% to $4.71 in pre-market trading. See how other analysts view this stock.

     

    Check This Out: Tyson Foods, Henry Schein And 3 Stocks To Watch Heading Into Monday

    Get the next $AXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXS
    $BBDC
    $CCAP
    $GDRX

    CompanyDatePrice TargetRatingAnalyst
    Waters Corporation
    $WAT
    2/10/2026$360.00In-line
    Evercore ISI
    Waters Corporation
    $WAT
    2/10/2026$425.00Buy
    Citigroup
    Waters Corporation
    $WAT
    2/10/2026$400.00Overweight
    Barclays
    HP Inc.
    $HPQ
    2/3/2026$20.00Neutral → Underperform
    BofA Securities
    GoodRx Holdings Inc.
    $GDRX
    1/22/2026$2.75Buy → Hold
    Jefferies
    Nouveau Monde Graphite Inc.
    $NMG
    1/20/2026$6.00Buy
    Maxim Group
    HP Inc.
    $HPQ
    1/16/2026$18.00Equal Weight → Underweight
    Barclays
    HP Inc.
    $HPQ
    1/13/2026$21.00Sell
    Goldman
    More analyst ratings

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hawley George acquired 766 shares, increasing direct ownership by 5% to 14,776 units (SEC Form 5)

    5 - Crescent Capital BDC, Inc. (0001633336) (Issuer)

    2/13/26 5:01:10 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    Bouek Kirill acquired 32 shares, increasing direct ownership by 3% to 1,088 units (SEC Form 5)

    5 - Crescent Capital BDC, Inc. (0001633336) (Issuer)

    2/13/26 4:59:30 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    Barrios Erik G acquired 227 shares, increasing direct ownership by 11% to 2,251 units (SEC Form 5)

    5 - Crescent Capital BDC, Inc. (0001633336) (Issuer)

    2/13/26 4:58:02 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Byers Stephen R bought $60,644 worth of shares (6,761 units at $8.97) and sold $50,926 worth of shares (5,671 units at $8.98), increasing direct ownership by 2% to 64,572 units (SEC Form 4)

    4 - Barings BDC, Inc. (0001379785) (Issuer)

    12/10/25 3:27:05 PM ET
    $BBDC
    Diversified Financial Services
    Finance

    Chief Financial Officer Lombard Gerhard bought $26,683 worth of shares (2,000 units at $13.34), increasing direct ownership by 6% to 34,284 units (SEC Form 4)

    4 - Crescent Capital BDC, Inc. (0001633336) (Issuer)

    11/18/25 4:11:44 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    Controller Bouek Kirill bought $3,133 worth of shares (200 units at $15.67), increasing direct ownership by 23% to 1,057 units (SEC Form 4)

    4 - Crescent Capital BDC, Inc. (0001633336) (Issuer)

    8/29/25 4:17:54 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Barclays resumed coverage on Waters with a new price target

    Barclays resumed coverage of Waters with a rating of Overweight and set a new price target of $400.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup resumed coverage on Waters with a new price target

    Citigroup resumed coverage of Waters with a rating of Buy and set a new price target of $425.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation

    FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE:WAT).  In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock that they held as of the close of business on February 5, 2026, the record date for the spin-off, with cash in lieu of any fractional shares of Waters common stock, and BD received $4 billion of cash. As of the closing of the transaction, BD's share

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AXS
    $BBDC
    $CCAP
    $GDRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Axis Capital Holdings Limited

    SCHEDULE 13G - AXIS CAPITAL HOLDINGS LTD (0001214816) (Subject)

    2/13/26 11:03:03 AM ET
    $AXS
    Property-Casualty Insurers
    Finance

    SEC Form 6-K filed by Noah Holdings Limited

    6-K - NOAH HOLDINGS LTD (0001499543) (Filer)

    2/13/26 6:07:32 AM ET
    $NOAH
    Investment Managers
    Finance

    SEC Form 6-K filed by Noah Holdings Limited

    6-K - NOAH HOLDINGS LTD (0001499543) (Filer)

    2/12/26 6:18:43 AM ET
    $NOAH
    Investment Managers
    Finance

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Matt Arens, CEO and Founder of Health Catalyst's Largest Shareholder, First Light Asset Management, Joins Board of Directors

    SALT LAKE CITY, Dec. 2, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst", or the ", Company, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Matt Arens, CEO and Founder of First Light Asset Management, LLC ("First Light"), has been appointed to serve as a member of Health Catalyst's board of directors ("Board"), effective Dec. 1, 2025. A shareholder since Health Catalyst's IPO in 2019, First Light is the Company's largest shareholder, and First Light and Mr. Arens collectively o

    12/2/25 6:59:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Healthmine Appoints Dwight Erskine as New Chief Executive Officer

    Healthmine, a leading member engagement and rewards platform for health plans, today announced that its Board of Directors has appointed Dwight Erskine as its new Chief Executive Officer, effective September 15, 2025. Erskine succeeds Bryce Williams, who will remain with the company during a transition period before moving into an advisory role. Erskine joins Healthmine as a seasoned leader with more than 25 years of experience in healthcare technology, transformation and analytics. He most recently served as Senior Vice President of Enterprise Transformation at VillageMD where he led the streamlining of clinical operations and scale value-based care delivery across the organization. Prio

    9/24/25 8:30:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Crescent Capital BDC Inc.

    SC 13G - Crescent Capital BDC, Inc. (0001633336) (Subject)

    11/26/24 10:37:47 AM ET
    $CCAP
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Crescent Capital BDC Inc.

    SC 13G - Crescent Capital BDC, Inc. (0001633336) (Subject)

    11/26/24 10:35:36 AM ET
    $CCAP
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Health Catalyst Inc

    SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)

    11/14/24 7:51:57 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $AXS
    $BBDC
    $CCAP
    $GDRX
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Crescent Capital BDC, Inc. Reschedules Earnings Release and Conference Call for Fourth Quarter and Fiscal Year Ended December 31, 2025

    LOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (the "Company") (NASDAQ:CCAP) today announced that it has rescheduled the release of its financial results and accompanying earnings webcast/conference call for the fourth quarter and fiscal year ended December 31, 2025. The Company will now release its financial results for the fourth quarter and fiscal year ended December 31, 2025 on Wednesday, February 25, 2026 after market close and host a webcast/conference call on Thursday, February 26, 2026 at 12:00 p.m. Eastern Time. Conference Call Information: The conference call will be broadcast live at 12:00 p.m. Eastern Time on the Investor Relations section of Cresce

    2/6/26 4:10:00 PM ET
    $CCAP
    Finance: Consumer Services
    Finance

    Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Fourth Quarter and Fiscal Year Ended December 31, 2025 Financial Results

    LOS ANGELES, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. ("Crescent BDC") (NASDAQ:CCAP) today announced it will release its financial results for the fourth quarter and fiscal year ended December 31, 2025 on Wednesday, February 18, 2026 after market close. Crescent BDC invites all interested persons to attend its webcast/conference call on Thursday, February 19, 2026 at 12:00 p.m. Eastern Time to discuss its fourth quarter and year ended December 31, 2025 financial results. Conference Call Information: The conference call will be broadcast live at 12:00 p.m. Eastern Time on the Investor Relations section of Crescent BDC's website at www.crescentbdc.com. Please visit the

    2/4/26 4:05:00 PM ET
    $CCAP
    Finance: Consumer Services
    Finance